Ampeptec Inc.
Ampeptec Inc.
ABOUT US
—
ABOUT US
—
Ampeptec is a peptide drug company developing multiple innovative long-acting peptides to improve patients’ comfort and quality of life.
Our APT3711 GLP-1 receptor agonist is a potential once a month injection and once a week oral drug for the treatment of diabetes and obesity. APT3711 has demonstrated twice the longer half-life as compared to Semaglutide. We believe that APT3711 GLP-1 receptor agonist would be the best-in-class for obesity as well as diabetes treatment as compared to commercially available once a weekly injection, daily consumed oral drugs, and other GLP-1 receptor agonist candidates in development.
Ampeptec is a peptide drug company developing multiple innovative long-acting peptides to improve patients’ comfort and quality of life.
Our APT3711 GLP-1 receptor agonist is a potential once a month injection and once a week oral drug for the treatment of diabetes and obesity. APT3711 has demonstrated twice the longer half-life as compared to Semaglutide. We believe that APT3711 GLP-1 receptor agonist would be the best-in-class for obesity as well as diabetes treatment as compared to commercially available once a weekly injection, daily consumed oral drugs, and other GLP-1 receptor agonist candidates in development.
PIPELINES
—
PIPELINES
—
NEWS
—
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
As well as the upfront cash, Merck & Co. is eligible to pay Hansoh Pharma up to $1.9 billion in milestone payments for the exclusive global license to the HS-10535. (Merck & Co.)
Diabetes Drug Market Size to Attain Around USD 132.36 Billion by 2034
The global diabetes drug market size was evaluated at USD 66 billion in 2023 and
Why the anti-obesity drug market could grow to $100 billion by 2030
Earlier this year, the global market for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, it could grow by more than 16 times to $100 billion, according to Goldman Sachs Research.
NEWS
—
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
As well as the upfront cash, Merck & Co. is eligible to pay Hansoh Pharma up to $1.9 billion in milestone payments for the exclusive global license to the HS-10535. (Merck & Co.)
Diabetes Drug Market Size to Attain Around USD 132.36 Billion by 2034
The global diabetes drug market size was evaluated at USD 66 billion in 2023 and
Why the anti-obesity drug market could grow to $100 billion by 2030
Earlier this year, the global market for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, it could grow by more than 16 times to $100 billion, according to Goldman Sachs Research.
Ampeptec, Inc.
442 Park West Drive
Grovetown, GA 30813
E-mail: info@ampeptec.com
Investors
Simrat Singh
Chief Operating Officer
E-mail: simrat.singh@ampeptec.com
Employment
Jackie Gay
Manager of Human Resources
E-mail: jackie.gay@ampeptec.com
Copyright © 2026 Ampeptec All Rights Reserved
Copyright © 2026 Ampeptec All Rights Reserved
